|
1
|
Ali Z, Yousaf N and Larkin J: Melanoma
epidemiology, biology and prognosis. EJC Suppl. 11:81–91. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar
|
|
3
|
Rastrelli M, Tropea S, Rossi CR and
Alaibac M: Melanoma: Epidemiology, risk factors, pathogenesis,
diagnosis and classification. In Vivo. 28:1005–1011.
2014.PubMed/NCBI
|
|
4
|
Gilchrest BA, Eller MS, Geller AC and Yaar
M: The pathogenesis of melanoma induced by ultraviolet radiation. N
Engl J Med. 340:1341–1348. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Pennello G, Devesa S and Gail M:
Association of surface ultraviolet B radiation levels with melanoma
and nonmelanoma skin cancer in United States blacks. Cancer
Epidemiol Biomarkers Prev. 9:291–297. 2000.PubMed/NCBI
|
|
6
|
Falzone L, Marconi A, Loreto C, Franco S,
Spandidos DA and Libra M: Occupational exposure to carcinogens:
Benzene, pesticides and fibers (Review). Mol Med Rep. 14:4467–4474.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nelemans PJ, Groenendal H, Kiemeney LA,
Rampen FH, Ruiter DJ and Verbeek AL: Effect of intermittent
exposure to sunlight on melanoma risk among indoor workers and
sun-sensitive individuals. Environ Health Perspect. 101:252–255.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Elwood JM and Jopson J: Melanoma and sun
exposure: An overview of published studies. Int J Cancer.
73:198–203. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Candido S, Rapisarda V, Marconi A,
Malaponte G, Bevelacqua V, Gangemi P, Scalisi A, McCubrey JA,
Maestro R, Spandidos DA, et al: Analysis of the
B-RafV600E mutation in cutaneous melanoma patients with
occupational sun exposure. Oncol Rep. 31:1079–1082. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Gandini S, Sera F, Cattaruzza MS, Pasquini
P, Picconi O, Boyle P and Melchi CF: Meta-analysis of risk factors
for cutaneous melanoma: II. Sun exposure. Eur J Cancer. 41:45–60.
2005. View Article : Google Scholar
|
|
11
|
White E, Kirkpatrick CS and Lee JA:
Case-control study of malignant melanoma in Washington state. I.
Constitutional factors and sun exposure. Am J Epidemiol.
139:857–868. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lazovich D, Vogel RI, Berwick M, Weinstock
MA, Anderson KE and Warshaw EM: Indoor tanning and risk of
melanoma: A case-control study in a highly exposed population.
Cancer Epidemiol Biomarkers Prev. 19:1557–1568. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Archier E, Devaux S, Castela E, Gallini A,
Aubin F, Le Maître M, Aractingi S, Bachelez H, Cribier B, Joly P,
et al: Carcinogenic risks of psoralen UV-A therapy and narrowband
UV-B therapy in chronic plaque psoriasis: A systematic literature
review. J Eur Acad Dermatol Venereol. 26(Suppl 3): 22–31. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
International Agency for Research on
Cancer Working Group on artificial ultraviolet (UV) light and skin
cancer: The association of use of sunbeds with cutaneous malignant
melanoma and other skin cancers: A systematic review. Int J Cancer.
120:1116–1122. 2007.
|
|
15
|
Wehner MR, Chren MM, Nameth D, Choudhry A,
Gaskins M, Nead KT, Boscardin WJ and Linos E: International
prevalence of indoor tanning: A systematic review and
meta-analysis. JAMA Dermatol. 150:390–400. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Bauer J and Garbe C: Acquired melanocytic
nevi as risk factor for melanoma development. A comprehensive
review of epidemiological data. Pigment Cell Res. 16:297–306. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Russo AE, Torrisi E, Bevelacqua Y,
Perrotta R, Libra M, McCubrey JA, Spandidos DA, Stivala F and
Malaponte G: Melanoma: Molecular pathogenesis and emerging target
therapies (Review). Int J Oncol. 34:1481–1489. 2009.PubMed/NCBI
|
|
18
|
Hawkes JE, Truong A and Meyer LJ: Genetic
predisposition to melanoma. Semin Oncol. 43:591–597. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bevona C, Goggins W, Quinn T, Fullerton J
and Tsao H: Cutaneous melanomas associated with nevi. Arch
Dermatol. 139:1620–1624; discussion 1624. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Seykora J and Elder D: Dysplastic nevi and
other risk markers for melanoma. Semin Oncol. 23:682–687.
1996.PubMed/NCBI
|
|
21
|
Watt AJ, Kotsis SV and Chung KC: Risk of
melanoma arising in large congenital melanocytic nevi: A systematic
review. Plast Reconstr Surg. 113:1968–1974. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Gandini S, Sera F, Cattaruzza MS, Pasquini
P, Abeni D, Boyle P and Melchi CF: Meta-analysis of risk factors
for cutaneous melanoma: I. Common and atypical naevi. Eur J Cancer.
41:28–44. 2005. View Article : Google Scholar
|
|
23
|
Olsen CM, Zens MS, Stukel TA, Sacerdote C,
Chang YM, Armstrong BK, Bataille V, Berwick M, Elwood JM, Holly EA,
et al: Nevus density and melanoma risk in women: A pooled analysis
to test the divergent pathway hypothesis. Int J Cancer.
124:937–944. 2009. View Article : Google Scholar :
|
|
24
|
Dessinioti C, Antoniou C, Katsambas A and
Stratigos AJ: Melanocortin 1 receptor variants: Functional role and
pigmentary associations. Photochem Photobiol. 87:978–987. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Goldstein AM and Tucker MA: Genetic
epidemiology of cutaneous melanoma: A global perspective. Arch
Dermatol. 137:1493–1496. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Soura E, Eliades PJ, Shannon K, Stratigos
AJ and Tsao H: Hereditary melanoma: Update on syndromes and
management: Genetics of familial atypical multiple mole melanoma
syndrome. J Am Acad Dermatol. 74:395–407; quiz 408–410. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Gruis NA, van der Velden PA, Sandkuijl LA,
Prins DE, Weaver-Feldhaus J, Kamb A, Bergman W and Frants RR:
Homozygotes for CDKN2 (p16) germline mutation in Dutch familial
melanoma kindreds. Nat Genet. 10:351–353. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zuo L, Weger J, Yang Q, Goldstein AM,
Tucker MA, Walker GJ, Hayward N and Dracopoli NC: Germline
mutations in the p16INK4a binding domain of CDK4 in familial
melanoma. Nat Genet. 12:97–99. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kanitakis J: Anatomy, histology and
immunohistochemistry of normal human skin. Eur J Dermatol.
12:390–399; quiz 400–401. 2002.PubMed/NCBI
|
|
30
|
Lin JY and Fisher DE: Melanocyte biology
and skin pigmentation. Nature. 445:843–850. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Curtin JA, Fridlyand J, Kageshita T, Patel
HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, et
al: Distinct sets of genetic alterations in melanoma. N Engl J Med.
353:2135–2147. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bastian BC: The molecular pathology of
melanoma: An integrated taxonomy of melanocytic neoplasia. Annu Rev
Pathol. 9:239–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Shain AH and Bastian BC: From melanocytes
to melanomas. Nat Rev Cancer. 16:345–358. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Pollock PM, Harper UL, Hansen KS, Yudt LM,
Stark M, Robbins CM, Moses TY, Hostetter G, Wagner U, Kakareka J,
et al: High frequency of BRAF mutations in nevi. Nat Genet.
33:19–20. 2003. View
Article : Google Scholar
|
|
35
|
Leonardi GC, Accardi G, Monastero R,
Nicoletti F and Libra M: Ageing: From inflammation to cancer. Immun
Ageing. 15:12018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Speeckaert R, van Geel N, Vermaelen KV,
Lambert J, Van Gele M, Speeckaert MM and Brochez L: Immune
reactions in benign and malignant melanocytic lesions: Lessons for
immunotherapy. Pigment Cell Melanoma Res. 24:334–344. 2011.
View Article : Google Scholar
|
|
37
|
Gray-Schopfer V, Wellbrock C and Marais R:
Melanoma biology and new targeted therapy. Nature. 445:851–857.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Farmer ER, Gonin R and Hanna MP:
Discordance in the histopathologic diagnosis of melanoma and
melanocytic nevi between expert pathologists. Hum Pathol.
27:528–531. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Chiriboga L, Meehan S, Osman I, Glick M,
de la Cruz G, Howell BS, Friedman-Jiménez G, Schneider RJ and Jamal
S: Endothelin-1 in the tumor microenvironment correlates with
melanoma invasion. Melanoma Res. 26:236–244. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Moro N, Mauch C and Zigrino P:
Metalloproteinases in melanoma. Eur J Cell Biol. 93:23–29. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Sandri S, Faião-Flores F, Tiago M,
Pennacchi PC, Massaro RR, Alves-Fernandes DK, Berardinelli GN,
Evangelista AF, de Lima Vazquez V, Reis RM and Maria-Engler SS:
Vemurafenib resistance increases melanoma invasiveness and
modulates the tumor microenvironment by MMP-2 upregulation.
Pharmacol Res. 111:523–533. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Falzone L, Salemi R, Travali S, Scalisi A,
McCubrey JA, Candido S and Libra M: MMP-9 overexpression is
associated with intragenic hypermethylation of MMP9 gene in
melanoma. Aging (Albany NY). 8:933–944. 2016. View Article : Google Scholar
|
|
43
|
Lee KR, Lee JS, Kim YR, Song IG and Hong
EK: Polysaccharide from Inonotus obliquus inhibits migration and
invasion in B16-F10 cells by suppressing MMP-2 and MMP-9 via
downregulation of NF-κB signaling pathway. Oncol Rep. 31:2447–2453.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Guarneri C, Bevelacqua V, Polesel J,
Falzone L, Cannavò PS, Spandidos DA, Malaponte G and Libra M: NF-κB
inhibition is associated with OPN/MMP 9 downregulation in cutaneous
melanoma. Oncol Rep. 37:737–746. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Vogelstein B, Papadopoulos N, Velculescu
VE, Zhou S, Diaz LA Jr and Kinzler KW: Cancer genome landscapes.
Science. 339:1546–1558. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Akbani R, Akdemir KC, Aksoy BA, Albert M,
Ally A, Amin SB, Arachchi H, Arora A, Auman JT, Ayala B, et al:
Cancer Genome Atlas Network: Genomic classification of cutaneous
melanoma. Cell. 161:1681–1696. 2015. View Article : Google Scholar
|
|
47
|
Hodis E, Watson IR, Kryukov GV, Arold ST,
Imielinski M, Theurillat JP, Nickerson E, Auclair D, Li L, Place C,
et al: A landscape of driver mutations in melanoma. Cell.
150:251–263. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Krauthammer M, Kong Y, Ha BH, Evans P,
Bacchiocchi A, McCusker JP, Cheng E, Davis MJ, Goh G, Choi M, et
al: Exome sequencing identifies recurrent somatic RAC1 mutations in
melanoma. Nat Genet. 44:1006–1014. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Chappell WH, Steelman LS, Long JM, Kempf
RC, Abrams SL, Franklin RA, Bäsecke J, Stivala F, Donia M, Fagone
P, et al: Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors:
Rationale and importance to inhibiting these pathways in human
health. Oncotarget. 2:135–164. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Wellbrock C, Karasarides M and Marais R:
The RAF proteins take centre stage. Nat Rev Mol Cell Biol.
5:875–885. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Raman M, Chen W and Cobb MH: Differential
regulation and properties of MAPKs. Oncogene. 26:3100–3112. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Carlino MS, Long GV, Kefford RF and Rizos
H: Targeting oncogenic BRAF and aberrant MAPK activation in the
treatment of cutaneous melanoma. Crit Rev Oncol Hematol.
96:385–398. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yuan TL and Cantley LC: PI3K pathway
alterations in cancer: Variations on a theme. Oncogene.
27:5497–5510. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Davies MA: The role of the PI3K-AKT
pathway in melanoma. Cancer J. 18:142–147. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Cohen C, Zavala-Pompa A, Sequeira JH,
Shoji M, Sexton DG, Cotsonis G, Cerimele F, Govindarajan B, Macaron
N and Arbiser JL: Mitogen-actived protein kinase activation is an
early event in melanoma progression. Clin Cancer Res. 8:3728–3733.
2002.PubMed/NCBI
|
|
56
|
Wang YF, Jiang CC, Kiejda KA, Gillespie S,
Zhang XD and Hersey P: Apoptosis induction in human melanoma cells
by inhibition of MEK is caspase-independent and mediated by the
Bcl-2 family members PUMA, Bim, and Mcl-1. Clin Cancer Res.
13:4934–4942. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Lovly CM, Dahlman KB, Fohn LE, Su Z,
Dias-Santagata D, Hicks DJ, Hucks D, Berry E, Terry C, Duke M, et
al: Routine multiplex mutational profiling of melanomas enables
enrollment in genotype-driven therapeutic trials. PLoS One.
7:e353092012. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Rubinstein JC, Sznol M, Pavlick AC, Ariyan
S, Cheng E, Bacchiocchi A, Kluger HM, Narayan D and Halaban R:
Incidence of the V600K mutation among melanoma patients with BRAF
mutations, and potential therapeutic response to the specific BRAF
inhibitor PLX4032. J Transl Med. 8:672010. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Davies H, Bignell GR, Cox C, Stephens P,
Edkins S, Clegg S, Teague J, Woffendin H, Garnett MJ, Bottomley W,
et al: Mutations of the BRAF gene in human cancer. Nature.
417:949–954. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Wan PTC, Garnett MJ, Roe SM, Lee S,
Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ,
Barford D and Marais R; Cancer Genome Project: Mechanism of
activation of the RAF-ERK signaling pathway by oncogenic mutations
of B-RAF. Cell. 116:855–867. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Richtig G, Hoeller C, Kashofer K,
Aigelsreiter A, Heinemann A, Kwong LN, Pichler M and Richtig E:
Beyond the BRAFV600E hotspot: Biology and clinical
implications of rare BRAF gene mutations in melanoma patients. Br J
Dermatol. 177:936–944. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Jakob JA, Bassett RL Jr, Ng CS, Curry JL,
Joseph RW, Alvarado GC, Rohlfs ML, Richard J, Gershenwald JE, Kim
KB, et al: NRAS mutation status is an independent prognostic factor
in metastatic melanoma. Cancer. 118:4014–4023. 2012. View Article : Google Scholar :
|
|
63
|
Giehl K: Oncogenic Ras in tumour
progression and metastasis. Biol Chem. 386:193–205. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Fedorenko IV, Gibney GT and Smalley KS:
NRAS mutant melanoma: Biological behavior and future strategies for
therapeutic management. Oncogene. 32:3009–3018. 2013. View Article : Google Scholar
|
|
65
|
Maertens O, Johnson B, Hollstein P,
Frederick DT, Cooper ZA, Messiaen L, Bronson RT, McMahon M, Granter
S, Flaherty K, et al: Elucidating distinct roles for NF1 in
melanomagenesis. Cancer Discov. 3:338–349. 2013. View Article : Google Scholar :
|
|
66
|
Whittaker SR, Theurillat JP, Van Allen E,
Wagle N, Hsiao J, Cowley GS, Schadendorf D, Root DE and Garraway
LA: A genome-scale RNA interference screen implicates NF1 loss in
resistance to RAF inhibition. Cancer Discov. 3:350–362. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Nissan MH, Pratilas CA, Jones AM, Ramirez
R, Won H, Liu C, Tiwari S, Kong L, Hanrahan AJ, Yao Z, et al: Loss
of NF1 in cutaneous melanoma is associated with RAS activation and
MEK dependence. Cancer Res. 74:2340–2350. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Krauthammer M, Kong Y, Bacchiocchi A,
Evans P, Pornputtapong N, Wu C, McCusker JP, Ma S, Cheng E, Straub
R, et al: Exome sequencing identifies recurrent mutations in NF1
and RASopathy genes in sun-exposed melanomas. Nat Genet.
47:996–1002. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Gibney GT and Smalley KS: An unholy
alliance: Cooperation between BRAF and NF1 in melanoma development
and BRAF inhibitor resistance. Cancer Discov. 3:260–263. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Beadling C, Jacobson-Dunlop E, Hodi FS, Le
C, Warrick A, Patterson J, Town A, Harlow A, Cruz F III, Azar S, et
al: KIT gene mutations and copy number in melanoma subtypes. Clin
Cancer Res. 14:6821–6828. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Handolias D, Salemi R, Murray W, Tan A,
Liu W, Viros A, Dobrovic A, Kelly J and McArthur GA: Mutations in
KIT occur at low frequency in melanomas arising from anatomical
sites associated with chronic and intermittent sun exposure.
Pigment Cell Melanoma Res. 23:210–215. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Shain AH, Yeh I, Kovalyshyn I, Sriharan A,
Talevich E, Gagnon A, Dummer R, North J, Pincus L, Ruben B, et al:
The genetic evolution of melanoma from precursor lesions. N Engl J
Med. 373:1926–1936. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Castellano M, Pollock PM, Walters MK,
Sparrow LE, Down LM, Gabrielli BG, Parsons PG and Hayward NK:
CDKN2A/16 is inactivated in most melanoma cell lines. Cancer Res.
57:4868–4875. 1997.PubMed/NCBI
|
|
74
|
Sharpless E and Chin L: The INK4a/ARF
locus and melanoma. Oncogene. 22:3092–3098. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Wu H, Goel V and Haluska FG: PTEN
signaling pathways in melanoma. Oncogene. 22:3113–3122. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Mirmohammadsadegh A, Marini A, Nambiar S,
Hassan M, Tannapfel A, Ruzicka T and Hengge UR: Epigenetic
silencing of the PTEN gene in melanoma. Cancer Res. 66:6546–6552.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Stahl JM, Cheung M, Sharma A, Trivedi NR,
Shanmugam S and Robertson GP: Loss of PTEN promotes tumor
development in malignant melanoma. Cancer Res. 63:2881–2890.
2003.PubMed/NCBI
|
|
78
|
Tsao H, Goel V, Wu H, Yang G and Haluska
FG: Genetic interaction between NRAS and BRAF mutations and
PTEN/MMAC1 inactivation in melanoma. J Invest Dermatol.
122:337–341. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Nogueira C, Kim KH, Sung H, Paraiso KH,
Dannenberg JH, Bosenberg M, Chin L and Kim M: Cooperative
interactions of PTEN deficiency and RAS activation in melanoma
metastasis. Oncogene. 29:6222–6232. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Shi H, Hugo W, Kong X, Hong A, Koya RC,
Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, et al:
Acquired resistance and clonal evolution in melanoma during BRAF
inhibitor therapy. Cancer Discov. 4:80–93. 2014. View Article : Google Scholar :
|
|
81
|
Damsky WE, Curley DP, Santhanakrishnan M,
Rosenbaum LE, Platt JT, Gould Rothberg BE, Taketo MM, Dankort D,
Rimm DL, McMahon M and Bosenberg M: β-catenin signaling controls
metastasis in Braf-activated Pten-deficient melanomas. Cancer Cell.
20:741–754. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Rimm DL, Caca K, Hu G, Harrison FB and
Fearon ER: Frequent nuclear/cytoplasmic localization of β-catenin
without exon 3 mutations in malignant melanoma. Am J Pathol.
154:325–329. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Ross MI and Gershenwald JE: Evidence-based
treatment of early-stage melanoma. J Surg Oncol. 104:341–353. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Luke JJ, Flaherty KT, Ribas A and Long GV:
Targeted agents and immunotherapies: Optimizing outcomes in
melanoma. Nat Rev Clin Oncol. 14:463–482. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Hodi FS, O'Day SJ, McDermott DF, Weber RW,
Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel
JC, et al: Improved survival with ipilimumab in patients with
metastatic melanoma. N Engl J Med. 363:711–723. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Hauschild A, Grob JJ, Demidov LV, Jouary
T, Gutzmer R, Millward M, Rutkowski P, Blank CU, Miller WH Jr,
Kaempgen E, et al: Dabrafenib in BRAF-mutated metastatic melanoma:
A multicentre, open-label, phase 3 randomised controlled trial.
Lancet. 380:358–365. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
McArthur GA, Chapman PB, Robert C, Larkin
J, Haanen JB, Dummer R, Ribas A, Hogg D, Hamid O, Ascierto PA, et
al: Safety and efficacy of vemurafenib in BRAF(V600E) and
BRAF(V600K) mutation-positive melanoma (BRIM-3): Extended follow-up
of a phase 3, randomised, open-label study. Lancet Oncol.
15:323–332. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Robert C, Long GV, Brady B, Dutriaux C,
Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C,
Kalinka-Warzocha E, et al: Nivolumab in previously untreated
melanoma without BRAF mutation. N Engl J Med. 372:320–330. 2015.
View Article : Google Scholar
|
|
89
|
Robert C, Karaszewska B, Schachter J,
Rutkowski P, Mackiewicz A, Stroiakovski D, Lichinitser M, Dummer R,
Grange F, Mortier L, et al: Improved overall survival in melanoma
with combined dabrafenib and trametinib. N Engl J Med. 372:30–39.
2015. View Article : Google Scholar
|
|
90
|
Long GV, Stroyakovskiy D, Gogas H,
Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A,
Grob JJ, et al: Dabrafenib and trametinib versus dabrafenib and
placebo for Val600 BRAF-mutant melanoma: A multicentre,
double-blind, phase 3 randomised controlled trial. Lancet.
386:444–451. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Ribas A, Puzanov I, Dummer R, Schadendorf
D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD,
et al: Pembrolizumab versus investigator-choice chemotherapy for
ipilimumab-refractory melanoma (KEYNOTE-002): A randomised,
controlled, phase 2 trial. Lancet Oncol. 16:908–918. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Weber JS, D'Angelo SP, Minor D, Hodi FS,
Gutzmer R, Neyns B, Hoeller C, Khushalani I, Miller WH Jr, Lao CD,
et al: Nivolumab versus chemotherapy in patients with advanced
melanoma who progressed after anti-CTLA-4 treatment (CheckMate
037): A randomised, controlled, open-label, phase 3 trial. Lancet
Oncol. 16:375–384. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Ascierto PA, McArthur GA, Dréno B,
Atkinson V, Liszkay G, Di Giacomo AM, Mandalà M, Demidov L,
Stroyakovskiy D, Thomas L, et al: Cobimetinib combined with
vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM):
Updated efficacy results from a randomised, double-blind, phase 3
trial. Lancet Oncol. 17:1248–1260. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Malas S, Harrasser M, Lacy KE and
Karagiannis SN: Antibody therapies for melanoma: New and emerging
opportunities to activate immunity (Review). Oncol Rep. 32:875–886.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
95
|
Zhang Y, Song Y and Gao Q: Increased
survival time of a patient with metastatic malignant melanoma
following immunotherapy: A case report and literature review. Oncol
Lett. 10:883–886. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Akiyama Y, Nonomura C, Kondou R, Miyata H,
Ashizawa T, Maeda C, Mitsuya K, Hayashi N, Nakasu Y and Yamaguchi
K: Immunological effects of the anti-programmed death-1 antibody on
human peripheral blood mononuclear cells. Int J Oncol.
49:1099–1107. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Larkin J, Lao CD, Urba WJ, McDermott DF,
Horak C, Jiang J and Wolchok JD: Efficacy and safety of nivolumab
in patients with BRAF V600 mutant and BRAF wild-type advanced
melanoma: A pooled analysis of 4 clinical trials. JAMA Oncol.
1:433–440. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Mangana J, Cheng PF, Schindler K, Weide B,
Held U, Frauchiger AL, Romano E, Kähler KC, Rozati S, Rechsteiner
M, et al: Analysis of BRAF and NRAS mutation status in advanced
melanoma patients treated with anti-CTLA 4 antibodies: Association
with overall survival. PLoS One. 10:e01394382015. View Article : Google Scholar
|
|
99
|
Robert C, Schachter J, Long GV, Arance A,
Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al
KEYNOTE-006 investigators: Pembrolizumab versus ipilimumab in
advanced melanoma. N Engl J Med. 372:2521–2532. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Simeone E and Ascierto PA:
Immunomodulating antibodies in the treatment of metastatic
melanoma: The experience with anti-CTLA-4, anti-CD137, and
anti-PD1. J Immunotoxicol. 9:241–247. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Zimmer L, Apuri S, Eroglu Z, Kottschade
LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, Krackhardt
AM, Loquai C, et al: Ipilimumab alone or in combination with
nivolumab after progression on anti-PD-1 therapy in advanced
melanoma. Eur J Cancer. 75:47–55. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
102
|
McCubrey JA, Steelman LS, Kempf CR,
Chappell WH, Abrams SL, Stivala F, Malaponte G, Nicoletti F, Libra
M, Bäsecke J, et al: Therapeutic resistance resulting from
mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
J Cell Physiol. 226:2762–2781. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Steelman LS, Chappell WH, Abrams SL, Kempf
RC, Long J, Laidler P, Mijatovic S, Maksimovic-Ivanic D, Stivala F,
Mazzarino MC, et al: Roles of the Raf/MEK/ERK and
PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity
to therapy-implications for cancer and aging. Aging (Albany NY).
3:192–222. 2011. View Article : Google Scholar
|
|
104
|
McCubrey JA, Steelman LS, Chappell WH,
Abrams SL, Franklin RA, Montalto G, Cervello M, Libra M, Candido S,
Malaponte G, et al: Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade
inhibitors: How mutations can result in therapy resistance and how
to overcome resistance. Oncotarget. 3:1068–1111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Van Allen EM, Wagle N, Sucker A, Treacy
DJ, Johannessen CM, Goetz EM, Place CS, Taylor-Weiner A, Whittaker
S, Kryukov GV, et al Dermatologic Cooperative Oncology Group of
Germany (DeCOG): The genetic landscape of clinical resistance to
RAF inhibition in metastatic melanoma. Cancer Discov. 4:94–109.
2014. View Article : Google Scholar :
|
|
106
|
Hugo W, Shi H, Sun L, Piva M, Song C, Kong
X, Moriceau G, Hong A, Dahlman KB, Johnson DB, et al: Non-genomic
and immune evolution of melanoma acquiring MAPKi resistance. Cell.
162:1271–1285. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Gray ES, Rizos H, Reid AL, Boyd SC,
Pereira MR, Lo J, Tembe V, Freeman J, Lee JH, Scolyer RA, et al:
Circulating tumor DNA to monitor treatment response and detect
acquired resistance in patients with metastatic melanoma.
Oncotarget. 6:42008–42018. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Santiago-Walker A, Gagnon R, Mazumdar J,
Casey M, Long GV, Schadendorf D, Flaherty K, Kefford R, Hauschild
A, Hwu P, et al: Correlation of BRAF Mutation status in
circulating-free dna and tumor and association with clinical
outcome across four BRAFi and MEKi clinical trials. Clin Cancer
Res. 22:567–574. 2016. View Article : Google Scholar
|
|
109
|
Girotti MR, Gremel G, Lee R, Galvani E,
Rothwell D, Viros A, Mandal AK, Lim KH, Saturno G, Furney SJ, et
al: Application of sequencing, liquid biopsies, and patient-derived
xenografts for personalized medicine in melanoma. Cancer Discov.
6:286–299. 2016. View Article : Google Scholar
|
|
110
|
Spranger S, Spaapen RM, Zha Y, Williams J,
Meng Y, Ha TT and Gajewski TF: Up-regulation of PD-L1, IDO, and
T(regs) in the melanoma tumor microenvironment is driven by CD8(+)
T cells. Sci Transl Med. 5:200ra1162013. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Donia M, Harbst K, van Buuren M, Kvistborg
P, Lindberg MF, Andersen R, Idorn M, Munir Ahmad S, Ellebæk E,
Mueller A, et al: Acquired immune resistance follows complete tumor
regression without loss of target antigens or IFNγ signaling.
Cancer Res. 77:4562–4566. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Spranger S, Bao R and Gajewski TF:
Melanoma-intrinsic β-catenin signalling prevents anti-tumour
immunity. Nature. 523:231–235. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Peng W, Chen JQ, Liu C, Malu S, Creasy C,
Tetzlaff MT, Xu C, McKenzie JA, Zhang C, Liang X, et al: Loss of
PTEN promotes resistance to T cell-mediated immunotherapy. Cancer
Disco. 6:202–216. 2016. View Article : Google Scholar
|
|
114
|
Zaretsky JM, Garcia-Diaz A, Shin DS,
Escuin-Ordinas H, Hugo W, Hu-Lieskovan S, Torrejon DY,
Abril-Rodriguez G, Sandoval S, Barthly L, et al: Mutations
associated with acquired resistance to PD 1 blockade in melanoma. N
Engl J Med. 375:819–829. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
115
|
Banna GL, Torino F, Marletta F, Santagati
M, Salemi R, Cannarozzo E, Falzone L, Ferraù F and Libra M:
Lactobacillus rhamnosus GG: An overview to explore the rationale of
its use in cancer. Front Pharmacol. 1(8): 6032017. View Article : Google Scholar
|
|
116
|
Gopalakrishnan V, Spencer CN, Nezi L,
Reuben A, Andrews MC, Karpinets TV, Prieto PA, Vicente D, Hoffman
K, Wei SC, et al: Gut microbiome modulates response to anti-PD-1
immunotherapy in melanoma patients. Science. 359:97–103. 2018.
View Article : Google Scholar
|
|
117
|
Routy B, Le Chatelier E, Derosa L, Duong
CPM, Alou MT, Daillère R, Fluckiger A, Messaoudene M, Rauber C,
Roberti MP, et al: Gut microbiome influences efficacy of PD-1-based
immunotherapy against epithelial tumors. Science. 359:91–97. 2018.
View Article : Google Scholar
|
|
118
|
Pappalardo F, Russo G, Candido S, Pennisi
M, Cavalieri S, Motta S, McCubrey JA, Nicoletti F and Libra M:
Computational modeling of PI3K/AKT and MAPK signaling pathways in
melanoma Cancer. PLoS One. 11:e01521042016. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Rambow F, Job B, Petit V, Gesbert F,
Delmas V, Seberg H, Meurice G, Van Otterloo E, Dessen P, Robert C,
et al: New functional signatures for understanding melanoma biology
from tumor cell lineage-specific analysis. Cell Reports.
13:840–853. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Pennisi M, Russo G, Di Salvatore V,
Candido S, Libra M and Pappalardo F: Computational modeling in
melanoma for novel drug discovery. Expert Opin Drug Discov.
11:609–621. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Chapman PB, Hauschild A, Robert C, Haanen
JB, Ascierto P, Larkin J, Dummer R, Garbe C, Testori A, Maio M, et
al BRIM-3 Study Group: Improved survival with vemurafenib in
melanoma with BRAF V600E mutation. N Engl J Med. 364:2507–2516.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Robert C, Thomas L, Bondarenko I, O'Day S,
Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, et al:
Ipilimumab plus dacarbazine for previously untreated metastatic
melanoma. N Engl J Med. 364:2517–2526. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Wolchok JD, Chiarion-Sileni V, Gonzalez R,
Rutkowski P, Grob JJ, Cowey CL, Lao CD, Wagstaff J, Schadendorf D,
Ferrucci PF, et al: Overall survival with combined nivolumab and
ipilimumab in advanced melanoma. N Engl J Med. 377:1345–1356. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Schachter J, Ribas A, Long GV, Arance A,
Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al:
Pembrolizumab versus ipilimumab for advanced melanoma: Final
overall survival results of a multicentre, randomised, open-label
phase 3 study (KEYNOTE-006). Lancet. 390:1853–1862. 2017.
View Article : Google Scholar : PubMed/NCBI
|
